Skip to content
Clinical Trials – home
SpainBack to Spain

Clinical trials in Labeaga – page 26

773 clinical trials in Labeaga, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Labeaga at a glance
773
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

773 trials in Labeaga

Open in trial search

Triple negative breast cancer+3

Not yet recruiting

Evaluation of DOTATATE and GOZETOTIDE for Diagnosis and Treatment in Patients with Solid Tumors and Brain Metastases

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dotatate
  • Sponsor:Medica Scientia Innovation Research S.L.

Phase 2 Study of Inhaled AGMB-447 and Salbutamol Sulfate in Adults with Idiopathic Pulmonary Fibrosis to Evaluate Lung Function, Safety and Tolerability

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol Sulfate
  • Sponsor:Agomab Spain S.L.U.

Transitional cell carcinoma+1

Not yet recruiting

Phase 3 Study of trastuzumab brengitecan versus platinum‑based chemotherapy in adults with HER2‑positive metastatic urothelial cancer after anti‑PD‑(L)1 therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Systimmune Inc.

Safety of allogeneic adipocyte-derived mesenchymal stromal cells expressing CXCR4 and IL‑10 in steroid‑refractory or ruxolitinib‑refractory acute graft‑versus‑host disease

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:CXCR4/IL10-MSCs
  • Sponsor:Fundacion Instituto De Investigacion Sanitaria De Navarra

Gastric cancer

Not yet recruiting

Immune Modulation Study of Rilvegostomig and Pembrolizumab in Patients with Advanced Gastric Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Vall D Hebron Institute Of Oncology

Graft versus host disease

Not yet recruiting

Study of mesenchymal stromal cells expressing CXCR4 and IL-10 for patients with acute Graft Versus Host Disease who do not respond to steroids or ruxolitinib

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:CXCR4/IL10-MSCs
  • Sponsor:Fundacion Instituto De Investigacion Sanitaria De Navarra

Breast cancer

Not yet recruiting

Discontinuation of anti‑HER2 therapy guided by ctDNA in patients with HER2‑positive metastatic breast cancer receiving pertuzumab and trastuzumab

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana

Phase Ib/II Study of Zongertinib Combined with Ribociclib and Trastuzumab in Patients with Metastatic ER‑positive/HER2‑positive Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Ribociclib
  • Sponsor:Solti Group

Study of elranatamab, mezigdomide and dexamethasone in patients with relapsed/refractory multiple myeloma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Elranatamab
  • Sponsor:Fundacion Pethema

Adenocarcinoma pancreas

Not yet recruiting

First‑Line Study of Zoldonrasib (RMC‑9805) Drug Combination vs Gemcitabine/Nab‑Paclitaxel in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Daraxonrasib
  • Sponsor:Revolution Medicines Inc.

A Phase 2 Study of LAD603 in Adults with Systemic Lupus Erythematosus and Active Skin Rash

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:LAD603
  • Sponsor:Almirall S.A.

Acute myeloid leukaemia

Not yet recruiting

A Phase 1/2 study of CHM-029 alone and in combination drug regimen in adults with newly diagnosed, relapsed or refractory Acute Myeloid Leukemia

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Charm Therapeutics Limited

Other cities in Spain

The busiest research cities in the country

All 210 cities in Spain
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.